Table 2.
Summary of Complications, Management, and Outcomes
| Observational Study (n = 1216) | RCT (n = 503) | All Patients (N = 1719) | |
|---|---|---|---|
| New bleeding | 77 (6) | 81 (16) | 158 (9) |
| None | 1138 (94) | 423 (84) | 1561 (91) |
| Skin only | 39 (3) | 59 (12) | 98 (6) |
| Mucosal | 38 (3) | 22 (4) | 60 (3) |
| Severe bleeding | 20 (2) | 11 (2) | 31 (2) |
| Transfusion | 18 (1) | 8 (2) | 26 (2) |
| Inotropic support | 55 (5) | 20 (4) | 75 (4) |
| Total parenteral fluid volume, mL/kga | 114 (99–129) | 125 (110–143) | 116 (102–133) |
| Received colloida | 547 (45) | 418 (83) | 965 (56) |
| Total colloid volumeb, mL/kg | 19 (13–25) | 25 (24–25) | 25 (15–29) |
| Clinical fluid overloada,c | 340 (28) | 173 (34) | 513 (30) |
| DHF according to WHO 1997 criteriaa,d | 796 (66) | 406 (81) | 1202 (70) |
| Death | 7 (<1) | 1 (<1) | 8 (<1) |
Continuous variables are summarized as median (interquartile range) and categorical variables as frequency (%).
Abbreviations: DHF, dengue hemorrhagic fever; RCT, randomized controlled trial; WHO, World Health Organization.
a Up to 14 missing values.
b Only includes patients who received a colloid infusion.
c Clinically detectable pleural effusion or ascites.
d Using all available acute and convalescent information.